2018 is already seeing big deals in the cancer therapy space with Celgene’s recent buyout of Impact Biomedicines, which develops a key drug for treating complex cancers.
Other big pharma names like Pfizer, Novartis, and GlaxoSmithKline have also been active in the last 5 years with key investments to cancer startups as they make bets to avoid missing out on strengthening their cancer drug pipelines.